C-CAR168 in Autoimmune Diseases Refractory to Standard Therapy

Phase 1, open-label, single-arm trial of C-CAR168 in multiple sclerosis (MS), myasthenia gravis (MG), Neuromyelitis Optica Spectrum Disorder (NMOSD) and 3 more, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Incidence and severity of Adverse Events at 24 months and Subsequent recommended dose of C-CAR168 at 24 months. Planned start Jul 2026; status: not yet recruiting.